Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

morning brief

Ex Sanofi boss joins Boston start-up

Chris Viehbacher joins other industry veterans as the newest board member of PureTech

- PMLiVE

Novartis and GSK complete oncology and vaccines swap

Follows Swiss company's decision to divest its BRAF and MEK inhibitors to Array BioPharma

- PMLiVE

Sovaldi-Daklinza combo cures hep C in co-infected HIV patients

Phase III trial of BMS and Gilead antivirals cured 97% of patients

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

Bristol-Myers Squibb (BMS) building

BMS buys immunotherapy specialist Flexus in $1.2bn deal

And signs new cancer research partnership with Rigel

- PMLiVE

Novo Nordisk’s oral GLP-1 analogue looks set for phase III

Semaglutide said to be one of the firm’s most promising prospects

- PMLiVE

GSK replaces head of US operations

Deidre Connelly to be replaced by Jack Bailey

- PMLiVE

GSK buys vaccine specialist GlycoVaxyn for $190m

Acquisition will expand GSK’s early vaccines pipeline

- PMLiVE

GSK sees COPD future in triple therapy

High hopes for once a day single inhaler

- PMLiVE

Novo Nordisk confirms public listing for IT unit

Will spin off its NNIT business as a separate company

- PMLiVE

GSK hints at more restructuring following income drop

Company experiences a tough 2014 with Advair competition and China bribery scandal

- PMLiVE

FDA approves BMS’ Evotaz for HIV

 Combines Reyataz with Gilead’s boosting agent cobicistat  

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links